219 related articles for article (PubMed ID: 24195711)
21. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
Ashby CR; Kehne JH; Bartoszyk GD; Renda MJ; Athanasiou M; Pierz KA; Seyfried CA
Eur J Pharmacol; 2013 Aug; 714(1-3):359-65. PubMed ID: 23872377
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
23. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
24. A new antidepressant.
Glazer WM
Behav Healthc; 2011 Sep; 31(6):39-40. PubMed ID: 22026116
[No Abstract] [Full Text] [Related]
25. ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
Hopkins CR
ACS Chem Neurosci; 2011 Oct; 2(10):554. PubMed ID: 22860155
[TBL] [Abstract][Full Text] [Related]
26. Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats.
Adamec R; Bartoszyk GD; Burton P
Eur J Pharmacol; 2004 Nov; 504(1-2):65-77. PubMed ID: 15507223
[TBL] [Abstract][Full Text] [Related]
27. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of vilazodone for the treatment of depressive and anxiety disorders.
Stuivenga M; Giltay EJ; Cools O; Roosens L; Neels H; Sabbe B
Expert Opin Pharmacother; 2019 Feb; 20(3):251-260. PubMed ID: 30475091
[TBL] [Abstract][Full Text] [Related]
29. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.
Roberts C; Hagan JJ; Bartoszyk GD; Kew JN
Eur J Pharmacol; 2005 Jul; 517(1-2):59-63. PubMed ID: 15978574
[TBL] [Abstract][Full Text] [Related]
30. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.
Laughren TP; Gobburu J; Temple RJ; Unger EF; Bhattaram A; Dinh PV; Fossom L; Hung HM; Klimek V; Lee JE; Levin RL; Lindberg CY; Mathis M; Rosloff BN; Wang SJ; Wang Y; Yang P; Yu B; Zhang H; Zhang L; Zineh I
J Clin Psychiatry; 2011 Sep; 72(9):1166-73. PubMed ID: 21951984
[TBL] [Abstract][Full Text] [Related]
31. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
[TBL] [Abstract][Full Text] [Related]
32. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.
Khan A; Sambunaris A; Edwards J; Ruth A; Robinson DS
Int Clin Psychopharmacol; 2014 Mar; 29(2):86-92. PubMed ID: 24247740
[TBL] [Abstract][Full Text] [Related]
33. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
34. Evidence for the use of vilazodone in the treatment of major depressive disorder.
Reinhold JA; Mandos LA; Lohoff FW; Rickels K
Expert Opin Pharmacother; 2012 Oct; 13(15):2215-24. PubMed ID: 22970859
[TBL] [Abstract][Full Text] [Related]
35. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
36. [Antidepressants, stressors and the serotonin 1A receptor].
Kirilly E; Gonda X; Bagdy G
Neuropsychopharmacol Hung; 2015 Jun; 17(2):81-9. PubMed ID: 26192901
[TBL] [Abstract][Full Text] [Related]
37. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Mathews M; Gommoll C; Chen D; Nunez R; Khan A
Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
[TBL] [Abstract][Full Text] [Related]
40. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.
Clayton AH; Gommoll C; Chen D; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Jul; 30(4):216-23. PubMed ID: 26039688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
